Abstract
Aim:To sodium valproate lore the effects of sodium valproate on serum inflammatory factors and s-100β levels in patients with emergency secondary epilepsy(SE).
Methods:This was a retrospective cohort of 120 patients with SE who received Sodium valproate that compared with a group who received carbamazepine regarding different therapeutic drugs. The general data, interleukin (IL)-2, IL-8, tumor necrosis factor (TNF)-α, neuron-specific enolase (NSE), serum acid calcium-binding protein s-100β, total effective rate(TER), seizure onset condition, and adverse reactions (Ars) of the two groups were compared at baseline and at 3 months later.
Results:There were no significant differences in age, gender, BMI, course of the disease, stroke type, or seizure type between the study groups (P>0.05). The results showed that IL-2 of the Sodium valproate group (53.17±4.95 µg/L) was lower versus Carbamazepine group (62.38±4.83 µg/L) (P<0.05). The IL-8 of the Sodium valproate grouppostoperatively (26.48 ± 2.73 µg/L) was lower versus Carbamazepine group (33.54±3.39 µg/L) (P<0.05). Postoperatively, the TNF-αin Sodium valproate group (32.18±4.26 µg/L) was lower versus the Carbamazepine group (41.03±4.92 µg/L) (P<0.05). The s-100β (0.29±0.15) µg/L in the Sodium valproate group was lower versus Carbamazepine group (0.54±0.14) µg/L (P<0.05). The TER of the Sodium valproate group (93.33%) was higher versus the Carbamazepine group of 75% (P<0.05). The number of epileptic seizures 0.81±0.08 times per year in the Sodium valproate group was versus 1.23±0.12 times per year in the Carbamazepine group. The duration of epilepsy in the Sodium valproate group (2.53±0.22 min/time) was shorter than that in the Carbamazepine group (3.08±0.24 min/time).
Conclusion: sodium valproate can drastically relieve the epileptic symptoms of patients with SE, and there was no great difference in ARs. Hence, it is safe and worthy of popularization and application.
Keywords
References
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.